701e70ac-31d2-4e78-95e1-3fa2bb466e83
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 63.2498288843258
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.380
- WNT_BETA_CATENIN_SIGNALING+0.330
- NOTCH_SIGNALING+0.270
- APICAL_JUNCTION+0.190
- MYOGENESIS+0.190
- MYC_TARGETS_V1+0.180
- UV_RESPONSE_UP+0.180
- DNA_REPAIR+0.170
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.150
- ANGIOGENESIS+0.120
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.570
- INTERFERON_GAMMA_RESPONSE-0.520
- ALLOGRAFT_REJECTION-0.360
- ANDROGEN_RESPONSE-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
- INFLAMMATORY_RESPONSE-0.290
- COMPLEMENT-0.240
- PROTEIN_SECRETION-0.230
- MTORC1_SIGNALING-0.210
- BILE_ACID_METABOLISM-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG154 | — | — | 0.832 |
| 2 | TCGA-EW-A424-01A-11R-A24H-07 | — | B | 0.818 |
| 3 | SRR17866843 | — | — | 0.810 |
| 4 | R108 | — | — | 0.808 |
| 5 | 20ed86b0-2e3d-44ec-88cd-eac5486fe15c | — | — | 0.804 |
| 6 | 620f38f7-7f22-41f3-a478-445f949006fe | — | — | 0.787 |
| 7 | c3b46d4b-4d9f-4d2d-bbca-c0dbd6901e56 | — | — | 0.787 |
| 8 | SRR2016936 | — | — | 0.775 |
| 9 | 8683d8f5-bba5-40a1-a460-ad6183d2302b | — | — | 0.773 |
| 10 | SRR11296875 | — | — | 0.771 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.330 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.270 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.180 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.150 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.090 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.080 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.050 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.020 | Inavolisib | — uncovered |